TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Snehal Patel
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences completed enrollment in the non-HLA-A*02 arm of its Phase III FLAMINGO-01 clinical trial, evaluating GLSI-100 immunotherapy for preventing breast cancer recurrences. The company is seeking regulatory approval to continue enrollment and believes the treatment could potentially serve approximately 88,000 new patients annually.

Insights
GLSI   positive

Company reported promising trial progress, completed patient enrollment, exploring expanded treatment potential, and considering patent extensions beyond 2040